Crinetics Pharmaceuticals upgraded by Jefferies with a new price target
$CRNX
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies upgraded Crinetics Pharmaceuticals from Hold to Buy and set a new price target of $55.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/11/2025 | Buy | TD Cowen | |
| 2/4/2025 | Peer Perform | Wolfe Research | |
| 1/22/2025 | $55.00 | Hold → Buy | Jefferies |
| 3/6/2024 | $68.00 | Buy | Citigroup |
| 1/16/2024 | $50.00 | Overweight | Morgan Stanley |
| 12/21/2023 | $35.00 | Hold | Jefferies |
| 11/20/2023 | $35.00 | Overweight | JP Morgan |
| 10/24/2023 | $52.00 → $50.00 | Overweight | Cantor Fitzgerald |
SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
SC 13G - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
S-8 - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
10-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Tobin "Toby" Schilke as chief financial officer, effective February 28, 2025. Mr. Schilke is a seasoned biopharma executive with over 25 years of global pharmaceutical experience. In prior roles, his leadership was instrumental in transforming several biotech companies from R&D-focused entities into fully integrated commercial organizations. "I am excited to welcome Toby to our senior leadership team during this transformational stage of our evolution into a global pharmaceutical company," said Scott Struthers, Ph.D., founder and chief executive officer of Crineti
SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos will lead the company's commercial strategy and operations for the potential launch of paltusotine, the first and only once-daily, oral, selective somatostatin receptor type 2 nonpeptide agonist for adults living with acromegaly and will lead pre-commercialization activities for the company's deep, innovative pipeline of candidates. "Isabel is a highly accomplished leader with broad commercial expertise ranging from launching therapies to leading early-stage commercial strategy," said Scott Struthers, Ph.D
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr. Cuddihy is a board-certified physician in endocrinology, diabetes and metabolism with more than 30 years of experience spanning clinical practice and pharmaceutical industry medical affairs. "Dr. Cuddihy's wealth of knowledge and experience both as a practicing physician in endocrinology and working within the pharmaceutical industry is an invaluable addition to our talented scientific leadership team," said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. "As we forg
SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that on March 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 95,675 shares of its common stock to fifteen new non-executive employees and 80,000 to one new executive employee; and granted an aggregate of 40,775 restricted stock unit ("RSU") awards to sixteen new non-executive employees and 52,000 to one new executive employee; in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the "2021 Inducement Plan"). The stock options and RSUs were granted a
Commercial Preparations On-Track Ahead of September 25, 2025 PDUFA Date Including Regulatory Review Process, Organizational Build, and Key Stakeholder Engagement Efforts Expecting to Initiate Four Late-Stage Trials and Additional Early-Stage Trials from Development Pipeline in 2025 Strong Financial Position with $1.4B Cash with Runway into 2029 Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today r
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Tobin "Toby" Schilke as chief financial officer, effective February 28, 2025. Mr. Schilke is a seasoned biopharma executive with over 25 years of global pharmaceutical experience. In prior roles, his leadership was instrumental in transforming several biotech companies from R&D-focused entities into fully integrated commercial organizations. "I am excited to welcome Toby to our senior leadership team during this transformational stage of our evolution into a global pharmaceutical company," said Scott Struthers, Ph.D., founder and chief executive officer of Crineti
SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, February 27 @ 4:30 p.m. ET Domestic: 1-800-267-6316International: 1-203-518-9783Conference ID: CRNXQ4 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely
Substantial, Rapid and Sustained Statistically Significant Reductions of Key Biomarkers Achieved Across Doses, Including up to 80% Mean Reduction of Androstenedione Meaningful Improvements Demonstrated in Multiple Clinical Signs and Symptoms of CAH Affecting Patient Health Safety and Efficacy Data Support Initiation of Phase 3 Clinical Trial Management to Host Investor Conference Call Today at 8:30 AM ET SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH) study of investigational atumelnant, a novel, once-daily oral adrenocorticotropic hormo
SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Tuesday, November 12 @ 4:30 p.m. ET Domestic: 1-800-579-2543International: 1-785-424-1789Conference ID: CRNXQ3 Participants can use the dial-in numbers above OR access the call via live webcast on the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants dial-in or re
4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
3 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
TD Cowen initiated coverage of Crinetics Pharmaceuticals with a rating of Buy
Wolfe Research initiated coverage of Crinetics Pharmaceuticals with a rating of Peer Perform
Jefferies upgraded Crinetics Pharmaceuticals from Hold to Buy and set a new price target of $55.00